KOD
Kodiak Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KOD
Kodiak Sciences Inc.
A company that developing novel therapeutics to treat chronic, and high-prevalence retinal diseases
1200 Page Mill Road, Palo Alto, CA 94304
--
Kodiak Sciences Inc., was incorporated as a limited liability company on June 22, 2009 under the name of Oligasis LLC. On September 8, 2015, it changed its name and incorporated in Delaware. The company is a clinical-stage biopharmaceutical company specializing in novel therapies for the treatment of chronic hyperepidemic retinal diseases. Kodiak Sciences Inc .'s most advanced product candidate is KSI-301, a biological therapy built using the company's antibody biopolymer coupling platform (ABC Platform) to maintain potent and potent drug levels in ocular tissue.
Company Financials
EPS
KOD has released its 2025 Q3 earnings. EPS was reported at -1.16, versus the expected -1.04, missing expectations. The chart below visualizes how KOD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
